Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have biopsy proven metastatic NSCLC (Stage IV).~2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved stable disease or a partial response.~3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR mutant-positive for 3 months and achieved stable disease, partial response or completely response.~4. Age 18 to 75 years old.~5. Patients must have measurable disease at baseline.~6. The amount of metastatic focus \<5.~7. ECOG score 0-2~8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.~9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)~10. Patients must provide written informed consent to participate in the study.~Exclusion Criteria:~1. Patients who previously received radiotherapy to the primary site.~2. Patient can't tolerate radiotherapy or targeted therapy;~3. Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SBRT plus TKI group (Type: EXPERIMENTAL): SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
- TKI treatment group (Type: ACTIVE_COMPARATOR): Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid

Based on this trial design, predict the completion outcome and termination type (if applicable).